Citations

Clear

2416 citation(s) found for "Yu, Jason L".

Reduction of Postoperative Hip Arthroscopy Pain With an Ultrasound-Guided Fascia Iliaca Block: A Prospective Randomized Controlled Trial
Glomset, John Larson, Tokish, John M. , Renfro, Suzanne D., Seckel, Tyler B., Adams, Kyle J. , Folk, Jason, Kim, Eugene S.

Mayo Clinic

The American Journal of Sports Medicine | January 30, 2020 | Volume: 48 | Issue: 3 | Pages: 682-688

10.1177/0363546519898205 | PMID 31999469 Get It

Background: Ultrasound-guided fascia iliaca blocks have been used for pain control after hip arthroscopy. There is little evidence regarding their effectiveness in comparison with other pain control modalities in patients who have undergone hip arthroscopy. Purpose: To compare the efficacy of ultrasound-guided fascia iliac block with intra-articular ropivacaine in controlling pain after hip arthroscopy. Study Design: Randomized controlled trial; Level of evidence, 2. Methods: Between 2015 and 2017, patients (N = 95) undergoing hip arthroscopy were randomly assigned to 2 groups. The first group received an ultrasound-guided fascia iliaca block with 50 to 60 mL of 0.35% ropivacaine. The second group received an intra-articular injection of 20 mL of 0.5% ropivacaine at the completion of the surgical case. Primary outcomes were postoperative pain scores in the recovery room; at postanesthesia care unit (PACU) discharge; and at 2 weeks, 6 weeks, and 3 months. Secondary outcomes included intraoperative and PACU narcotic usage (converted to morphine equivalent use) as well as readmission rates, PACU recovery time, and postoperative nausea and vomiting. Results: Postoperative pain across all points did not significantly differ between the groups. Intraoperative and PACU narcotics did not differ significantly between the groups. Readmission rates, PACU recovery time, and postoperative nausea and vomiting did not significantly differ between the groups. There were no associated complications in either group. Conclusion: Ultrasound-guided fascia iliaca block for hip arthroscopy had no clinical advantage when compared with onetime intra-articular ropivacaine injection. Registration: NCT02365961 (ClinicalTrials.gov identifier).
Magician’s Corner: 4. Image Segmentation with U-Net
Erickson, Bradley J. , Cai, Jason , Erickson, Bradley J

Mayo Clinic

Radiology: Artificial Intelligence | January 29, 2020 | Volume: 2 | Issue: 1 | Pages: e190161

10.1148/ryai.2020190161 | PMID 33937814 Get It

Characteristics and outcomes of patients with normal left atrial pressure undergoing transcatheter mitral valve repair
Sims, Jason R. , Reeder, Guy S., Nkomo, Vuyisile T. , Nishimura, Rick A., Rihal, Charanjit S. , Eleid, Mackram F. , Nkomo, Vuyisile T , Nishimura, Rick , Guerrero, Mayra , Alkhouli, Mohamad , Rihal, Charanjit S.

Mayo Clinic

Heart | January 24, 2020 | Volume: 106 | Issue: 12 | Pages: 898-903

10.1136/heartjnl-2019-316133 | PMID 31980440 Get It

Objective A subset of patients at the time of transcatheter mitral valve repair (TMVR) will have normal left atrial pressure (LAP) (<13 mm Hg) despite having severe mitral regurgitation (MR). The goal of this study was to determine clinical characteristics and outcomes in patients with normal LAP undergoing TMVR. Methods A single-centre retrospective cohort of consecutive patients who underwent transcatheter edge-to-edge mitral valve clip and continuous LAP monitoring between 5/1/2014 and 5/1/2018 was analysed. One-year mortality was compared by Kaplan–Meier survival curves. Multivariable analysis was performed to identify predictors of normal LAP and 1 year mortality. Results Of the 204 patients undergoing TMVR, 65% were men and the mean age was 81. Of these patients, 31 (15%) had normal LAP (mean LAP 10.5 mm Hg, mean V wave 16.5 mm Hg) and 173 had elevated LAP (mean LAP 19 mm Hg, mean V wave 32.5 mm Hg). The prevalence of severe MR was not different between groups, although the normal LAP group had significantly lower effective regurgitant orifice area and regurgitant volume. Other notable baseline characteristics including prior cardiac surgery, atrial fibrillation, hypertension, diabetes, congestive heart failure, body mass index, mechanism of MR and ejection fraction were similar between groups. However, there was an increased prevalence of chronic lung disease (CLD) (45.2% vs 17.3%, p<0.001) in the normal LAP group. On multivariate analysis, the only significant predictor of normal LAP was the presence of CLD (OR 4.79 (1.83–12.36), p=0.001) and 1-year mortality was significantly higher in the normal LAP group (32.3% vs 12.7%, p=0.006). After adjustment for comorbidities, normal LAP was no longer a predictor of 1-year mortality (RR 1.62 (0.64–4.06), p=0.32); however, CLD (RR 3.44 (1.37–8.67), p=0.01) remained a statistically significant predictor. Conclusion Normal LAP at the time of TMVR is associated with a higher incidence of CLD which independently predicts increased 1-year mortality. In patients with CLD and apparently severe MR, measurement of LAP may help identify those with lower likelihood of benefit from TMVR.
Traumatic Cranio-Orbital Injury: Reconstruction Using Extraocular Muscles
Oh, Christine , Lin, Jason , Lettieri, Salvatore C.

Mayo Clinic

Journal of Craniofacial Surgery | January 24, 2020 | Volume: 31 | Issue: 3 | Pages: e258-e259

10.1097/scs.0000000000006218 | PMID 31977689 Get It

Abstract Cranio-orbital trauma is an uncommon yet devastating injury, especially one in the setting of a high-energy gunshot wound. Such injuries were historically reported in the setting of military conflict, and are associated with vision-threatening complications, often resulting in anophthalmos. The authors report a case of a self-inflicted gunshot wound to the eye, which requires orbital enucleation with exposed frontal lobe dura. To address the exposed dura, the extraocular muscles were utilized from the enucleation procedure to cover the defect in the acute setting prior to final staged reconstruction.
The kinesin-5 tail domain directly modulates the mechanochemical cycle of the motor domain for anti-parallel microtubule sliding
Bodrug, Tatyana , Wilson-Kubalek, Elizabeth M., Nithianantham, Stanley , Thompson, Alex F. , Alfieri, April, Gaska, Ignas , Major, Jennifer , Debs, Garrett , Inagaki, Sayaka , Gheber, Larisa , McKenney, Richard J. , Milligan, Ronald A., Stumpff, Jason , Rosenfeld, Steven S. , Forth, Scott , Gheber, Larisa , Sindelar, Charles Vaughn , Al-Bassam, Jawdat , Forth, Scott , Gutierrez, Pedro

Mayo Clinic

eLife | January 20, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.51131 | PMID 31958056 Get It

Kinesin-5 motors organize mitotic spindles by sliding apart microtubules. They are homotetramers with dimeric motor and tail domains at both ends of a bipolar minifilament. Here, we describe a regulatory mechanism involving direct binding between tail and motor domains and its fundamental role in microtubule sliding. Kinesin-5 tails decrease microtubule-stimulated ATP-hydrolysis by specifically engaging motor domains in the nucleotide-free or ADP states. Cryo-EM reveals that tail binding stabilizes an open motor domain ATP-active site. Full-length motors undergo slow motility and cluster together along microtubules, while tail-deleted motors exhibit rapid motility without clustering. The tail is critical for motors to zipper together two microtubules by generating substantial sliding forces. The tail is essential for mitotic spindle localization, which becomes severely reduced in tail-deleted motors. Our studies suggest a revised microtubule-sliding model, in which kinesin-5 tails stabilize motor domains in the microtubule-bound state by slowing ATP-binding, resulting in high-force production at both homotetramer ends.
Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN)
Aschenbrenner, Andrew J. , James, Bryan D. , Wang, Guoqiao , Lim, Yen Ying , Benzinger, Tammie L.S. , Cruchaga, Carlos , Goate, Alison , Xiong, Chengjie , Perrin, Richard J. , Buckles, Virginia, Berman, Sarah , Chhatwal, Jasmeer P. , Fagan, Anne M. , Farlow, Martin R. , O’Connor, Antoinette , Graff‐Radford, Neill R. , Gräber, Susanne, Martins, Ralph N. , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Morris, John C. , Bateman, Randall J. , Hassenstab, Jason , Network, Dominantly Inherited Alzheimer, Cruchaga, Carlos , O'Connor, Antoinette , Bateman, Randall J , Masters, Colin L , Xiong, Chengjie , Benzinger, Tammie L S , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , McDade, Eric , Xiong, Chengjie , Allegri, Ricardo , Ghetti, Bernardino , Goldman, Jill , Karch, Celeste M. , Lee, Jae‐Hong , Schofield, Peter R. , Network, Dominantly Inherited Alzheimer, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 219-228

10.1002/alz.12010 | PMID 31914221 Get It

AbstractIntroductionAlthough some members of families with autosomal dominant Alzheimer's disease mutations learn their mutation status, most do not. How knowledge of mutation status affects clinical disease progression is unknown. This study quantifies the influence of mutation awareness on clinical symptoms, cognition, and biomarkers.MethodsMutation carriers and non‐carriers from the Dominantly Inherited Alzheimer Network (DIAN) were stratified based on knowledge of mutation status. Rates of change on standard clinical, cognitive, and neuroimaging outcomes were examined.ResultsMutation knowledge had no associations with cognitive decline, clinical progression, amyloid deposition, hippocampal volume, or depression in either carriers or non‐carriers. Carriers who learned their status mid‐study had slightly higher levels of depression and lower cognitive scores.DiscussionKnowledge of mutation status does not affect rates of change on any measured outcome. Learning of status mid‐study may confer short‐term changes in cognitive functioning, or changes in cognition may influence the determination of mutation status.
An International Multicenter Evaluation of Type 5 Long QT Syndrome
Roberts, Jason D. , Asaki, S. Yukiko , Mazzanti, Andrea , Bos, J. Martijn , Tuleta, Izabela , Muir, Alison , Crotti, Lia , Kutyifa, Valentina , Shoemaker, M. Benjamin , Johnsrude, Christopher L. , Aiba, Takeshi , Marcondes, Luciana, Baban, Anwar , Udupa, Sharmila, Dechert, Brynn E. , Fischbach, Peter , Knight, Linda M., Kukavica, Deni , Stallmeyer, Birgit, Giudicessi, John R. , Spazzolini, Carla , Cadrin‐Tourigny, Julia , Simpson, Christopher S. , Roston, Thomas M. , Hajjaji, Imane El , Yousif, Maisoon D. , Gula, Lorne J. , Leong‐Sit, Peter , Chavali, Nikhil, Landstrom, Andrew P. , Marcus, Gregory M. , Dittmann, Sven , Wilde, Arthur A.M. , Behr, Elijah R. , Tfelt‐Hansen, Jacob , Kaski, Juan Pablo , Gow, Robert M., Aziz, Peter F. , Abrams, Dominic J. , Skinner, Jonathan R. , Kaufman, Elizabeth S. , Roden, Dan M. , Zaręba, Wojciech , Schulze‐Bahr, Eric , Etheridge, Susan P. , Priori, Silvia G. , Ackerman, Michael J. , Crotti, Lia , Behr, Elijah Raphael , Landstrom, Andrew P , Bos, Johan M , Tfelt-Hansen, Jacob , Skinner, Jonathan R , Abrams, Dominic J , Baban, Anwar , Kaski, Juan P , Johnsrude, Christopher , Mazzanti, Andrea , Cadrin-Tourigny, Julia , Zareba, Wojciech , Spazzolini, Carla , Priori, Silvia , Marcus, Gregory M , Krahn, Andrew D. , Aiba, Takeshi , Knight, Linda M., Vittinghoff, Eric , Shimamoto, Keiko , Tadros, Rafik , Duff, Henry J. , Wijeyeratne, Yanushi D. , Scheinman, Melvin M , Pérez, Marco , Drago, Fabrizio , Gollob, Michael H. , Shimizu, Wataru , Roden, Dan M. , Schwartz, Peter J.

Mayo Clinic

Circulation | January 16, 2020 | Volume: 141 | Issue: 6 | Pages: 429-439

10.1161/circulationaha.119.043114 | PMID 31941373 Get It

Background: Insight into type 5 long QT syndrome (LQT5) has been limited to case reports and small family series. Improved understanding of the clinical phenotype and genetic features associated with rare KCNE1 variants implicated in LQT5 was sought through an international multicenter collaboration. Methods: Patients with either presumed autosomal dominant LQT5 (N = 229) or the recessive Type 2 Jervell and Lange-Nielsen syndrome (N = 19) were enrolled from 22 genetic arrhythmia clinics and 4 registries from 9 countries. KCNE1 variants were evaluated for ECG penetrance (defined as QTc >460 ms on presenting ECG) and genotype-phenotype segregation. Multivariable Cox regression was used to compare the associations between clinical and genetic variables with a composite primary outcome of definite arrhythmic events, including appropriate implantable cardioverter-defibrillator shocks, aborted cardiac arrest, and sudden cardiac death. Results: A total of 32 distinct KCNE1 rare variants were identified in 89 probands and 140 genotype positive family members with presumed LQT5 and an additional 19 Type 2 Jervell and Lange-Nielsen syndrome patients. Among presumed LQT5 patients, the mean QTc on presenting ECG was significantly longer in probands (476.9±38.6 ms) compared with genotype positive family members (441.8±30.9 ms, P <0.001). ECG penetrance for heterozygous genotype positive family members was 20.7% (29/140). A definite arrhythmic event was experienced in 16.9% (15/89) of heterozygous probands in comparison with 1.4% (2/140) of family members (adjusted hazard ratio [HR] 11.6 [95% CI, 2.6–52.2]; P =0.001). Event incidence did not differ significantly for Type 2 Jervell and Lange-Nielsen syndrome patients relative to the overall heterozygous cohort (10.5% [2/19]; HR 1.7 [95% CI, 0.3–10.8], P =0.590). The cumulative prevalence of the 32 KCNE1 variants in the Genome Aggregation Database, which is a human database of exome and genome sequencing data from now over 140 000 individuals, was 238-fold greater than the anticipated prevalence of all LQT5 combined (0.238% vs 0.001%). Conclusions: The present study suggests that putative/confirmed loss-of-function KCNE1 variants predispose to QT prolongation, however, the low ECG penetrance observed suggests they do not manifest clinically in the majority of individuals, aligning with the mild phenotype observed for Type 2 Jervell and Lange-Nielsen syndrome patients.
Lymphedema Signs, Symptoms, and Diagnosis in Women Who Are in Minority and Low-Income Groups and Have Survived Breast Cancer
Flores, Ann Marie , Nelson, Jason , Sowles, Lee, Stephenson, Rebecca G. , Robinson, K. , Sander, Antoinette P. , Blot, William J. , Cheville, Andrea

Mayo Clinic

Physical Therapy | January 11, 2020 | Volume: 100 | Issue: 3 | Pages: 487-499

10.1093/ptj/pzaa002 | PMID 32031628 Get It

Abstract Background Breast cancer–related lymphedema (BCRL) is a well-known side effect of cancer and its treatment with wide-ranging prevalence estimates. Objective This study describes associations between breast cancer–related lymphedema (BCRL) signs, symptoms, and diagnosis for women who were African American, white, or had a low income and survived breast cancer. Design This is a cross-sectional, observational study that used a computer-assisted telephone interview. Methods Women who had survived breast cancer were queried on the presence of 5 lymphedema signs and symptoms (edema in the breast, axilla, arm, and/or hand; tissue fibrosis; pitting; hemosiderin staining; heaviness) and whether they had a diagnosis of BCRL. Relationships between signs/symptoms and diagnosis for each group were evaluated with kappa and chi-square statistics. Results The study sample included 528 women who had survived breast cancer (266 white and 262 African American), with 514 reporting complete data on household income; 45% of the latter reported an annual household income of ≤$20,000. Women who were African American or had a low income were nearly twice as likely as women who were white to have any of 8 signs/symptoms of BCRL. Regardless of race and income, &gt;50% of women with all BCRL signs and symptoms reported that they were not diagnosed with BCRL. Limitations The main limitations of our study are the lack of medical chart data and longitudinal design. Conclusions Women who were African American or had a low income and had survived breast cancer had a greater burden of BCRL signs and symptoms than women who were white. The lack of a strong association between BCRL signs, symptoms, and diagnosis suggests that BCRL may be underdiagnosed. These findings suggest that more rigorous screening and detection of BCRL—especially for women who are African American or have a low income—may be warranted. Cancer rehabilitation programs may be able to fill this gap.
052: Lung Cancer in Patients Younger than 50 or Older than 80 Years of Age at Diagnosis
Visbal, A, Ebbert, Jon O. , Zhang, Z, Molina, Julian R. , Sheu, Sheh‐Yi , Nichols, Francis, Williams, B, Sheu, S, Wampfler, Jason A. , Nichols, Francis C., Yang, Ping

Mayo Clinic

American Journal of Epidemiology | January 8, 2020 | Volume: 161 | Issue: Supplement_1 | Pages: S13-S13

10.1093/aje/161.supplement_1.s13c Get It

Evidence Regarding Medication Overuse Headache in Children and Adolescents: Protocol for a Systematic Review
VanderPluym, Juliana H. , Gautreaux, Jessica , Burch, Rebecca , Whitaker, Evans , Roberts, Jason , Turner, Dana P. , Gelfand, Amy A. , Roberts, Jason , Gelfand, Amy A , VanderPluym, Juliana

Mayo Clinic

Headache: The Journal of Head and Face Pain | January 8, 2020 | Volume: 60 | Issue: 1 | Pages: 171-177

10.1111/head.13726 | PMID 31913513 Get It

Objectives This proposed systematic review will identify the existing evidence on medication‐overuse headache in children and adolescents. Background A number of medications have been shown to be effective for acute treatment of migraine in children and adolescents. However, patients may find they need to use their acute medications more frequently when migraine frequency is high. This has led to concern about their potential to develop medication‐overuse headache. Methods We will search PubMed, Embase, Web of Science, PsycINFO, and Cochrane databases from their inception to present time. We will also search conference proceedings of the last 4 scientific meetings of relevant societies and scan the reference lists of studies identified through the search. Study designs will include case series, cross‐sectional, cohort, case‐control, and interventional studies. Participants will include children and adolescents under 18 years of age with primary headache disorders. We aim to determine whether frequency of acute medication use is associated with headache frequency in children and adolescents. Outcomes of interest include: (1) headache frequency; (2) change in headache frequency, with time and in relationship to use of acute medications; and (3) headache‐related disability. We will also review data addressing treatment/management of medication overuse or medication‐overuse headache in children and adolescents. Relevant comparators will be withdrawal vs reduction of acute medication, initiation of preventive therapy vs no initiation with or without withdrawal of acute medication, and initiation of preventive therapy early vs late. Outcomes of interest include (1) days of acute medication use; (2) headache frequency; (3) change in headache frequency; and (4) headache‐related disability. After screening for inclusion, 2 team members will independently review and extract relevant data, and any discrepancies will be resolved through discussion and arbitration. We will assess risk of bias using appropriate tools (Cochrane Risk of Bias for randomized controlled trials (RCT) and Newcastle‐Ottawa Score for observational studies). Data will be summarized descriptively in text and tables. Results This systematic review will provide an overview of the available evidence on medication‐overuse headache in children and adolescents. Conclusions Findings from this review will aid clinicians by clarifying for them the current state of the evidence base, and will inform design of future research on this topic.